

543  
C1  
organ rejection, miscarriage, multiple sclerosis, inflammatory bowel disease, atherosclerosis, and graft versus host disease, which method comprises administering to the patient an effective amount of apoptotic bodies.

---

20. (New) The method of claim 19, wherein the apoptotic bodies are in a liquid suspension along with viable cells.

21. (New) The method of claim 20, wherein the apoptotic bodies comprise from 10% to 90% of the cellular portion of the suspension.

B1  
22. (New) The method of claim 21, wherein the apoptotic bodies comprise from 30% to 70% of the cellular portion of the suspension.

23. (New) The method of claim 19, wherein the apoptotic bodies are derived from extracorporeal treatment of blood cells compatible with those of the mammalian patient.

24. (New) The method of claim 19, wherein the apoptotic bodies are derived from established cultured cell lines.

25. (New) The method of claim 23, wherein the blood cells are white blood cells of blood compatible with that of the mammalian patient.

26. (New) The method of claim 25, wherein the blood cells are the patient's own white blood cells.

27. (New) The method of claim 26, wherein the blood cells are the patient's own T lymphocytes.

B<sub>1</sub> 28. (New) The method of claim 19, further comprising administering to a human patient a dosage of apoptotic bodies comprising from 10,000 to 10,000,000 apoptotic bodies per kilogram body weight of the patient.

29. (New) The method of claim 28, wherein the dosage contains from 500,000 to 5,000,000 apoptotic bodies per kilogram body weight of the patient.

30. (New) The method of claim 28, wherein the dosage contains from 1,500,000 to 4,000,000 apoptotic bodies per kilogram body weight of the patient.--

( Please add the following new claims 31-45: )

--31. (New) A composition which comprises apoptotic bodies in an amount effective for the treatment and/or prophylaxis in mammalian patients of a T-cell-mediated or inflammatory disorder selected from the group consisting of psoriasis, rheumatoid

arthritis, scleroderma, lupus, diabetes mellitus, organ rejection, miscarriage, multiple sclerosis, inflammatory bowel disease, atherosclerosis, and graft versus host disease.

32. (New) The composition of claim 31, wherein the apoptotic bodies are in a liquid suspension along with viable cells.

33. (New) The composition of claim 32, wherein the apoptotic bodies comprise from 10% to 90% of the cellular portion of the suspension.

B1 34. (New) The composition of claim 33, wherein the apoptotic bodies comprise from 30% to 70% of the cellular portion of the suspension.

35. (New) The composition of claim 31, wherein the apoptotic bodies are derived from extracorporeal treatment of blood cells compatible with blood cells of the mammalian patient to be treated.

36. (New) The composition of claim 31, wherein the apoptotic bodies are derived from established cultured cell lines.

37. (New) The composition of claim 35, wherein the blood cells are white blood cells of blood compatible with blood of the mammalian patient to be treated.

38. (New) The composition of claim 37, wherein the blood cells are white blood cells from the mammalian patient to be treated.

39. (New) The composition of claim 37, wherein the blood cells are the patient's are T lymphocytes from the mammalian patient to be treated.

40. (New) The composition of claim 31, wherein a dose of said composition comprises from 10,000 to 10,000,000 apoptotic bodies per kilogram body weight of the patient to be treated.

B1 41. (New) The composition of claim 40, wherein a dose of said composition comprises from 500,000 to 5,000,000 apoptotic bodies per kilogram body weight of the patient to be treated.

42. (New) The composition of claim 40, wherein a dose of said composition comprises from 1,500,000 to 4,000,000 apoptotic bodies per kilogram body weight of the patient to be treated.

43. (New) The composition of claim 31, wherein said composition further comprises a pharmaceutical excipient.

44. (New) The composition of claim 31, wherein said composition further comprises additional biologically active material.

45. (New) The composition of claim 44, wherein said additional biologically active material is selected from the group consisting of cytokines, hormones and products of stressed cells.--

---